QuidelOrtho Co. (NASDAQ:QDEL) Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its holdings in QuidelOrtho Co. (NASDAQ:QDEL) by 3.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 94,213 shares of the company’s stock after selling 2,938 shares during the quarter. Sei Investments Co. owned 0.14% of QuidelOrtho worth $4,197,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Blue Trust Inc. grew its position in QuidelOrtho by 188.0% during the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company’s stock valued at $58,000 after purchasing an additional 844 shares in the last quarter. Spire Wealth Management bought a new stake in QuidelOrtho during the 4th quarter valued at approximately $74,000. KBC Group NV boosted its holdings in QuidelOrtho by 122.9% in the 4th quarter. KBC Group NV now owns 3,437 shares of the company’s stock valued at $153,000 after purchasing an additional 1,895 shares during the period. Captrust Financial Advisors acquired a new position in QuidelOrtho in the 3rd quarter valued at approximately $238,000. Finally, CIBC Asset Management Inc boosted its stake in QuidelOrtho by 14.2% during the fourth quarter. CIBC Asset Management Inc now owns 6,564 shares of the company’s stock worth $292,000 after buying an additional 816 shares in the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Stock Up 1.5 %

Shares of QDEL stock opened at $34.63 on Thursday. QuidelOrtho Co. has a 52-week low of $29.74 and a 52-week high of $49.45. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -1.14 and a beta of 0.10. The firm’s 50-day moving average is $39.62 and its 200-day moving average is $41.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. Sell-side analysts predict that QuidelOrtho Co. will post 2.3 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on QDEL. UBS Group increased their price objective on QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday, February 13th. Jefferies Financial Group started coverage on QuidelOrtho in a research report on Tuesday, December 10th. They set a “hold” rating and a $43.00 target price for the company. Citigroup raised QuidelOrtho from a “neutral” rating to a “buy” rating and raised their price target for the stock from $44.00 to $50.00 in a research report on Wednesday, December 11th. StockNews.com lowered QuidelOrtho from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Finally, Royal Bank of Canada decreased their price objective on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $51.20.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.